A multi-center cross-sectional study to explore cancer patients’ views on facilitators and barriers for the implementation of oncological exercise therapy - Scorecard - MDSpire

A multi-center cross-sectional study to explore cancer patients’ views on facilitators and barriers for the implementation of oncological exercise therapy

  • By

  • Dominik Morlok

  • Laura Bieniosek

  • Hansjörg Baurecht

  • Melanie Reitz

  • Thomas Okon

  • Janina Meuer

  • Christine Welker

  • Wolfgang Herr

  • Tobias Pukrop

  • Sabine Einhell

  • Anika Berling-Ernst

  • Annalena Wehner

  • Mirko Brandes

  • Sebastian Theurich

  • Bernardine Madl

  • Louisa Sell

  • Thorsten Schmidt

  • Patrick Jahn

  • Carlotta Evers

  • Rebecca Zimmer

  • Renee Stark

  • Hajo Zeeb

  • Michael Leitzmann

  • Freerk T. Baumann

  • Anne Herrmann

  • June 10, 2026

  • 0 min

Share

Clinical Scorecard: A Cross-Sectional Study Across Multiple Centers Investigating Cancer Patients' Perspectives on Barriers and Facilitators to Oncological Exercise Therapy Implementation

At a Glance

CategoryDetail
Condition
Key MechanismsOncological exercise therapy (OET) improves patient outcomes including fatigue, quality of life, and survival in certain cancer types, supported by evidence.
Target Population
Care Setting

Key Highlights

  • 79% of patients felt physically capable of participating in OET.
  • 85% reported feeling mentally capable of engaging in OET.
  • 76% expressed high motivation to participate in OET.
  • 83% felt they had sufficient time to engage in OET.
  • Only 48% were offered OET by healthcare providers.

Guideline-Based Recommendations

Diagnosis

  • Patients should be assessed for eligibility for OET based on their cancer diagnosis and treatment status.

Management

  • Healthcare providers should routinely inform patients about OET as part of their treatment plan.
  • Assess patient readiness for OET before recommending participation.

Monitoring & Follow-up

  • Patient engagement and outcomes in OET should be monitored to evaluate effectiveness.

Risks

  • Potential risks of inactivity and lack of information about OET should be addressed.

Patient & Prescribing Data

Cancer patients in Germany, primarily those with breast cancer, lymphoma, leukemia, and colon cancer, including those undergoing follow-up care.

Patients are willing and able to participate in OET but often lack access and information.

Clinical Best Practices

  • Implement tailored strategies to improve patient access to OET.
  • Enhance communication between healthcare providers and patients regarding OET options.
  • Train healthcare providers about OET to improve patient communication.

Related Resources & Content

Original Source(s)

A multi-center cross-sectional study to explore cancer patients’ views on facilitators and barriers for the implementation of oncological exercise therapy

  • by Dominik Morlok, Laura Bieniosek, Hansjörg Baurecht, Melanie Reitz, Thomas Okon, Janina Meuer, Christine Welker, Wolfgang Herr, Tobias Pukrop, Sabine Einhell, Anika Berling-Ernst, Annalena Wehner, Mirko Brandes, Sebastian Theurich, Bernardine Madl, Louisa Sell, Thorsten Schmidt, Patrick Jahn, Carlotta Evers, Rebecca Zimmer, Renee Stark, Hajo Zeeb, Michael Leitzmann, Freerk T. Baumann, Anne Herrmann

  • June 10, 2026

Related Content

The value of robot-assisted gastrectomy in the treatment of gastric cancer: a systematic review and meta-analysis

Correction: Editorial: Epigenomics and metabolomics: pioneering new frontiers in breast cancer research and treatment

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min